We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

6 hedge funds and large institutions have $1.11M invested in Grace Therapeutics in 2013 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,020% more capital invested

Capital invested by funds: $10K → $1.11M (+$1.1M)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

50% more funds holding

Funds holding: 4 → 6 (+2)

0.32% more ownership

Funds ownership: 0% → 0.32% (+0.32%)

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$891K
2
PA
Perceptive Advisors
New York
+$479K
3
U
UBS
Switzerland
+$5.95K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.98K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$4K

GRCE Hedge Fund Activity: Q3 2013 in Review

6 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2013, worth a combined $1.11M — up 11,020% from $10K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new GRCE positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $891K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $4K sold.

  • 6 institutional investors held Grace Therapeutics (GRCE) as of Q3 2013, up from 4 in Q2 2013.
  • Funds reported $1.11M of Grace Therapeutics stock for Q3 2013, up 11,020% quarter-over-quarter.
  • 3 funds opened new Grace Therapeutics positions in Q3 2013 and 1 closed out, a net change of +2 holders.
  • The largest Grace Therapeutics buyer in Q3 2013 was Bank of Montreal, an estimated $891K added.
  • The largest Grace Therapeutics seller in Q3 2013 was Tower Research Capital (TRC), an estimated $4K sold.

Based on aggregated 13F filings for Q3 2013.